Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is

TD Cowen reaffirmed its confidence in Vertex Pharmaceuticals (NASDAQ:VRTX), maintaining a Buy rating and a $525.00 price target. The firm has highlighted Vertex as its top large-cap (L.C.) biotech pick for the year 2025.

Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight rating and a $533.00 price target on the company's stock. The endorsement follows Vertex's impressive quarterly revenue results and a solid initial financial outlook for the year 2025.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.